Hepatitis Monthly

Published by: Kowsar

Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis

Seyed Moayed Alavian 1 , 2 , 3 , * and Mohammad Saeid Rezaee-Zavareh 2 , 3 , 4
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
3 Meta-analysis Study Group for Treatment of Hepatitis C, Iran Hepatitis Network, Tehran, IR Iran
4 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: September 01, 2016, 16 (9); e41077
  • Published Online: August 22, 2016
  • Article Type: Review Article
  • Received: August 2, 2016
  • Revised: August 7, 2016
  • Accepted: August 14, 2016
  • DOI: 10.5812/hepatmon.41077

To Cite: Alavian S M, Rezaee-Zavareh M S. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis, Hepat Mon. 2016 ; 16(9):e41077. doi: 10.5812/hepatmon.41077.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345(1): 41-52[DOI][PubMed]
  • 3. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62(4): 1190-200[DOI][PubMed]
  • 4. Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016; 16(3): 35106[DOI][PubMed]
  • 5. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6): 2164-70[DOI][PubMed]
  • 6. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 21-41[DOI][PubMed]
  • 7. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res. 2014; 110: 79-93[DOI][PubMed]
  • 8. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015; 3(2): 73-4[DOI][PubMed]
  • 9. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4)
  • 10. Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol. 2016; 29(3): 282-96[DOI]
  • 11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264-9
  • 12. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014; 72(1): 39[DOI][PubMed]
  • 13. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366(3): 216-24[DOI][PubMed]
  • 14. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatol. 2012; 55(3): 742-8[DOI]
  • 15. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013; 58(4): 655-62[DOI][PubMed]
  • 16. Chayama K, Suzuki Y, Ikeda K, Toyota J, Karino Y, Kawakami Y. All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial. Hepatol. 2013; 58: 313
  • 17. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014; 60(3): 490-9[DOI][PubMed]
  • 18. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384(9954): 1597-605[DOI][PubMed]
  • 19. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59(6): 2083-91[DOI][PubMed]
  • 20. Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat. 2015; 22(2): 158-65[DOI]
  • 21. Iio E, Shimada N, Abe H, Atsukawa M, Yoshiza K, Takaguchi K. Efficacy of Daclatasvir/Asunaprevir According to Resistance Associated Variants in Chronic Hepatitis C Genotype1b. Hepatol. 2015; 62: 749-50
  • 22. Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2016; [DOI]
  • 23. Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, et al. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 2016; 13(6): 418-23[DOI][PubMed]
  • 24. Kinugasa H, Ikeda F, Takaguchi K, Mori C, Matsubara T, Shiraha H, et al. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. Antivir Ther. 2016; 21(1): 37-44[DOI][PubMed]
  • 25. Kumada H, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol. 2016; 31(1): 14-22[DOI][PubMed]
  • 26. Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis. Ther Apher Dial. 2016; 21(10): 1744-9987
  • 27. Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, et al. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016; [DOI][PubMed]
  • 28. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016; 14: 14[DOI]
  • 29. Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016; 12: 12
  • 30. Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016; 22(10): 13379
  • 31. Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, et al. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. J Med Virol. 2016; [DOI][PubMed]
  • 32. Nam HC, Lee HL, Yang H, Song MJ. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol. 2016; 22(2): 259-66[DOI][PubMed]
  • 33. Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016; 7(7): 179[DOI][PubMed]
  • 34. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014; 146(2): 420-9[DOI][PubMed]
  • 35. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Brau N, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015; 313(17): 1728-35[DOI][PubMed]
  • 36. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015; 62(5): 1204-6[DOI][PubMed]
  • 37. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015; 313(17): 1736-44[DOI][PubMed]
  • 38. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, et al. Daclatasvir + asunaprevir + beclabuvir +/- ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016; 36(2): 189-97[DOI][PubMed]
  • 39. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012; 12(9): 671-7
  • 40. Dore GJ, Lawitz E, Hezode C, Shafran SD, Ramji A, Tatum HA, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015; 148(2): 355-366 e1[DOI][PubMed]
  • 41. Jensen D, Sherman KE, Hezode C, Pol S, Zeuzem S, de Ledinghen V, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015; 63(1): 30-7[DOI][PubMed]
  • 42. Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, et al. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. Clin Infect Dis. 2015; 61(5): 817-25[DOI][PubMed]
  • 43. Hezode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015; 27(10)
  • 44. Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, et al. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol. 2016; 22(12): 3418-31[DOI][PubMed]
  • 45. Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao JH. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Int Soci Interferon Cytokine Res. 2016;
  • 46. Santagostino E, Pol S, Olveira A, Reesink HW, van Erpecum K, Bogomolov P, et al. Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naive or prior relapsers to peginterferon alfa-2a/ribavirin. Haemophilia. 2016; [DOI][PubMed]
  • 47. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015; 64(6): 948-56[DOI][PubMed]
  • 48. Izumi N, Yokosuka O, Kawada N, Osaki Y, Yamamoto K, Sata M, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther. 2014; 19(5): 501-10[DOI][PubMed]
  • 49. Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016; 22(4): 446-58[DOI]
  • 50. Zeuzem S, Hezode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol. 2016; 64(2): 292-300[DOI][PubMed]
  • 51. Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post kidney transplantation setting. Transpl Int. 2016; 20(10): 12799
  • 52. Gane E, Stedman C, Garg V, George S, Kieffer T, Krop J. An interferon- and ribavirin-free 12-week regimen of once-daily vx-135 and daclatasvir in treatment-naive patients with genotype 1 hcv infection. J Hepatol. 2014; 60(1): 528-9
  • 53. Guidelines Approved by the Guidelines Review Committee. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version 2015;
  • 54. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3): 211-21[DOI][PubMed]
  • 55. Pol S, Bourliere M, Lucier S, De Ledinghen V, Zoulim F, Dorival-Mouly C. LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather. J Hepatol. 2015; 62: 258-9[DOI]
  • 56. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8): 714-25[DOI][PubMed]
  • 57. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 64(6): 1224-31[DOI][PubMed]
  • 58. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493-505[DOI][PubMed]
  • 59. Welzel TM, Herzer K, Ferenci P, Petersen J, Gschwantler M, Cornberg M. P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program. J Hepatol. 62: 619-20
  • 60. Rockstroh JK, Welzel TM, Ingiliz P, Petersen J, van der Valk M, Herzer K. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter compassionate use program. Hepatol. 2015; 623: 728-9
  • 61. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465(7294): 96-100[DOI][PubMed]
  • 62. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol. 2011; 85(13): 6353-68[DOI][PubMed]
  • 63. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol. 2011; 54(5): 1069-72[DOI][PubMed]
  • 64. Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015; 20(5): 535-43[DOI][PubMed]
  • 65. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016; 39(7): 589-611[DOI][PubMed]
  • 66. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012; 56(10): 5387-96[DOI][PubMed]
  • 67. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012; 56(10): 5230-9[DOI][PubMed]
  • 68. Bourliere M, Oules V. , Ansaldi C, Adhoute X, Castellani P. Sofosbuvir as backbone of interferon free treatments. Digest Liver Dis. 2014; 46: 212-20
  • 69. Alavian SM. Sofosbuvir has come out of the magic box. Hepat Mon. 2013; 13(12): 16916[DOI][PubMed]
  • 70. Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, et al. Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline. Hepat Mon. 2016; 16(8)[DOI]
  • 71. Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol. 2016; 22(22): 5285-92
  • 72. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014; 60(4): 872-84[DOI][PubMed]
  • 73. Summary of product characteristics. 2016;
  • 74. Highlights of prescribing information. 2016;
  • 75. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61(4): 1127-35[DOI][PubMed]
  • 76. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016; 63(5): 1430-41[DOI][PubMed]
  • 77. Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016; 36(7): 971-6[DOI]
  • 78. Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, et al. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016; [DOI][PubMed]
  • 79. Hézode C, Abergel A, Chas J, Conti F, Cotte L, Tateo M. Sat-131 sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the french daclatasvir atu programme infected with hcv genotypes 4, 5 and 6. J Hepatol. 2015; 62: 755
  • 80. Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsics T. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS. 2016; 30(7): 1039-47
  • 81. Herzer K, Welzel TM, Ferenci P, Petersen J, Gschwantler M, Cornberg M. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program. Hepatol. 2015; 62: 341
  • 82. Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation -The CO23 ANRS CUPILT study. J Hepatol. 2016; 1(16): 30253-7
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments